BINEX Co. Ltd (053030) - Total Liabilities

Latest as of September 2025: ₩117.14 Billion KRW ≈ $79.38 Million USD

Based on the latest financial reports, BINEX Co. Ltd (053030) has total liabilities worth ₩117.14 Billion KRW (≈ $79.38 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of BINEX Co. Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.

BINEX Co. Ltd - Total Liabilities Trend (2004–2024)

This chart illustrates how BINEX Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 053030 total asset value.

BINEX Co. Ltd Competitors by Total Liabilities

The table below lists competitors of BINEX Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
De Licacy Industrial Co Ltd
TW:1464
Taiwan NT$11.72 Billion
ISC Fresh Water Investment SOCIMI SA
MC:YISC
Spain €128.90 Million
Origin Property PCL
BK:ORI
Thailand ฿42.79 Billion
West Wits Mining Ltd
AU:WWI
Australia AU$22.12 Million
SPRINGFIELD PROP. LS-125
F:9MZ
Germany €145.51 Million
Cypark Resources Berhad
KLSE:5184
Malaysia RM2.28 Billion
Capral Ltd
AU:CAA
Australia AU$239.10 Million
Panatlântica S.A
SA:PATI3
Brazil R$738.68 Million

Liability Composition Analysis (2004–2024)

This chart breaks down BINEX Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BINEX Co. Ltd net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.62 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.63 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BINEX Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BINEX Co. Ltd (2004–2024)

The table below shows the annual total liabilities of BINEX Co. Ltd from 2004 to 2024.

Year Total Liabilities Change
2024-12-31 ₩97.78 Billion
≈ $66.26 Million
+29.19%
2023-12-31 ₩75.69 Billion
≈ $51.29 Million
-29.14%
2022-12-31 ₩106.80 Billion
≈ $72.38 Million
+16.00%
2021-12-31 ₩92.07 Billion
≈ $62.39 Million
-4.96%
2020-12-31 ₩96.88 Billion
≈ $65.65 Million
+129.10%
2019-12-31 ₩42.29 Billion
≈ $28.66 Million
+3.17%
2018-12-31 ₩40.99 Billion
≈ $27.78 Million
+5.04%
2017-12-31 ₩39.02 Billion
≈ $26.44 Million
+6.76%
2016-12-31 ₩36.55 Billion
≈ $24.77 Million
+14.32%
2015-12-31 ₩31.97 Billion
≈ $21.67 Million
+28.80%
2013-12-31 ₩24.82 Billion
≈ $16.82 Million
-52.18%
2012-12-31 ₩51.90 Billion
≈ $35.17 Million
+72.44%
2011-12-31 ₩30.10 Billion
≈ $20.40 Million
+105.73%
2007-12-31 ₩14.63 Billion
≈ $9.91 Million
+1.63%
2006-12-31 ₩14.40 Billion
≈ $9.76 Million
+6.15%
2005-12-31 ₩13.56 Billion
≈ $9.19 Million
-26.46%
2004-12-31 ₩18.44 Billion
≈ $12.50 Million
--

About BINEX Co. Ltd

KQ:053030 Korea Pharmaceuticals
Market Cap
$132.31 Million
₩195.24 Billion KRW
Market Cap Rank
#18211 Global
#804 in Korea
Share Price
₩6260.00
Change (1 day)
-1.26%
52-Week Range
₩5940.00 - ₩18490.00
All Time High
₩36100.00
About

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more